H5019
11-Hydroxy-Δ9-tetrahydrocannabinol
vacuum-dried powder
Synonym(e):
7-Hydroxy-Δ1-tetrahydrocannabinol
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
Über diesen Artikel
Empirische Formel (Hill-System):
C21H30O3
CAS-Nummer:
Molekulargewicht:
330.46
UNSPSC Code:
41116107
MDL number:
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenform
vacuum-dried powder
drug control
USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
format
neat
storage temp.
−20°C
SMILES string
CCCCCc1cc(O)c2[C@@H]3C=C(CO)CC[C@H]3C(C)(C)Oc2c1
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Lagerklasse
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Identification of 9 -tetrahydrocannabinol and metabolites in man.
M E Wall et al.
Journal of the American Chemical Society, 94(24), 8579-8581 (1972-11-29)
Cynthia Coulter et al.
Journal of analytical toxicology, 32(8), 653-658 (2008-11-15)
An analytical procedure for the determination of Delta9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-Delta9-tetrahydrocannabinol (THCA), and 11-hydroxy-Delta9-tetrahydrocannabinol (11-OH-THC) in whole blood has been developed and validated using liquid chromatography with tandem mass spectral detection (MS). Cannabinoids present in the blood samples were quantified using
Erin L Karschner et al.
Clinical chemistry, 57(1), 66-75 (2010-11-17)
Sativex(®), a cannabis extract oromucosal spray containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD), is currently in phase III trials as an adjunct to opioids for cancer pain treatment, and recently received United Kingdom approval for treatment of spasticity. There are indications